Introduction
============

Low back pain is a major disabling condition that has a substantial social, economic, and health care impact and is increasing in prevalence [@B1]-[@B16]. An assessment by the US Burden of Disease Collaborators reported low back pain as the number one cause of disability [@B1]. Even though modalities for managing chronic low back pain continue to increase, the accurate cause of low back pain is determined in a very small proportion of patients, with disc herniation and spinal stenosis contributing to pain in a minority of patients, identified with ease and managed with therapies based on moderate evidence [@B4], [@B17], [@B18]. A multitude of treatment modalities, including surgical interventions, conservative modalities, chiropractic therapy, drug therapy, and interventional therapies continue to increase at a pace considered as uncontrollable, with escalating health care costs associated with numerous complications and the failure of some therapies [@B4], [@B6]-[@B19]. The accurate cause of low back pain is not determined in the majority of patients and in the cases where it is determined, costs, disability, and failed therapies are escalating.

Pathophysiology
---------------

The intervertebral disc has long been considered a common source of low back pain with pain caused by disc herniation or with pain emanating from pathologic changes within the disc itself [@B4], [@B20]-[@B23]. Discogenic pain was proposed even earlier than disc herniation with reports of discogenic pain published in 1932 and disc herniation in 1934 [@B20], [@B24], [@B25]. Pain originating from intervertebral discs without disc herniation has been described as discogenic pain, internal disc disruption, and painful degenerative disc disease [@B20]-[@B23]. However, discogenic pain has been poorly defined and its existence itself is being questioned with rather exceedingly controversial diagnostic and treatment modalities [@B4], [@B6]-[@B8], [@B10], [@B11], [@B14]-[@B16], [@B26]-[@B31]. Debate and controversies in reference to discogenic pain and its management are based on a lack of consensus on the definition of discogenic pain itself, poor prognosis with expensive surgical care, a lack of extensive published data from nonsurgical care, and the escalating utilization of multiple modalities and overall health care costs [@B4], [@B6]-[@B8], [@B10], [@B11], [@B14]-[@B16], [@B26]-[@B31].

While intervertebral disc degeneration is an age-related process that is asymptomatic in most individuals, pathologic degeneration can be a major source of pain and disability [@B4], [@B20]-[@B22]. "Discogenic low back pain" refers specifically to the pain caused by internal disc disruption (IDD) as proposed by Crock [@B32] as a condition marked by alteration in the internal structure and metabolic functions of the intervertebral disc. However, discogenic pain also has been described as a separate entity [@B20]-[@B22]. Consequently, the prevalence of pain due to IDD was reported to be 39% and 42% in patients suffering with chronic low back pain[@B33], [@B34], in contrast to primary lumbar discogenic pain which was reported in 26% when no other cause was suspected [@B35]. Peng et al [@B21] assessed the natural history of discogenic low back pain with IDD in 156 patients which constituted 56% of the sample and showed 87% of the patients continued their symptoms or suffered with additional symptoms.

Debate not only exists concerning the diagnosis, but also with therapeutic modalities. There have been dismal results with various surgical and nonsurgical interventions and a natural history of discogenic pain which continues to be present even 4 years after the failure of conservative management modalities [@B20]-[@B22].

Epidural Injections
-------------------

Epidural injections for managing chronic axial or discogenic pain is not well established and not well-known, but continually debated and appears to be one of the most common interventions performed for managing axial low back pain without disc herniation[@B4], [@B10], [@B11], [@B14]-[@B16], [@B20], [@B36]-[@B38]. The evidence continues to emerge in reference to the role of epidural injections for managing axial or discogenic low back pain. In the past, multiple studies included patients without separating disc herniation from discogenic pain as well as without eliminating facet joint pain or sacroiliac joint pain, which has led to an inordinately high failure rate. As an alternative to surgical fusion or intradiscal therapies, epidural injections have been proposed [@B36]-[@B38]. Their effectiveness has been demonstrated in randomized controlled trials and systematic reviews [@B4], [@B10], [@B11], [@B14]-[@B16], [@B20], [@B36]-[@B38]. However, care must be taken to exclude patients with facet joint or sacroiliac joint pain. Manchikanti et al [@B36], [@B37], in 2 randomized controlled trials with 120 patients in each trial, reported significant improvement as defined by the criteria of 50% or more reduction in pain scores and improvement in functional status.

Objectives
----------

Comparative studies are not available on the various approaches for managing chronic lumbar discogenic pain after ruling out facet joint and sacroiliac joint pain. We sought to evaluate the efficacy of the caudal and lumbar interlaminar approaches of epidural injections in managing chronic, intractable, persistent axial or discogenic low back pain after ruling out facet joint and sacroiliac joint pain and after partial or no response to conservative management with a 2-year follow-up, utilizing 2 published randomized trials with identical protocols [@B36], [@B37].

Materials and Methods
=====================

This assessment was performed from 2 previously published randomized controlled trials [@B36], [@B37] conducted in a tertiary referral interventional pain management center in the United States by the same group of investigators utilizing identical protocols. The trials [@B36], [@B37] and this analysis were conducted with internal resources. Institutional Review Board approval was obtained for both trials and they were registered with the US Clinical Trial Registry with assigned numbers of National Clinical Trial (NCT) NCT00370799 and NCT00681447. The trials were conducted based on Consolidated Standards of Reporting Trials guidance.

Both manuscripts [@B36], [@B37] included in this analysis have described in detail the patients, pre-enrollment assessment results, interventions, inclusion and exclusion criteria, description of interventions, additional and cointerventions, objectives and outcomes, randomization, sequence generation, allocation concealment, implementation, blinding, sample size calculation, and appropriate statistical methodology. All the patients who participated in these trials were recruited from a practice that provides interventional pain management services. Salient features are described below.

Interventions
-------------

The protocols specified caudal and lumbar interlaminar epidural injections. The patients in both trials were divided into 60 patients in each group who received either local anesthetic only or local anesthetic with a steroid. For caudal epidural injections, a total of 10 mL of solution (10 mL of 0.5% lidocaine or 9 mL of lidocaine with 1 mL of steroid) and for lumbar interlaminar epidural injections, a total of 6 mL of solution (6 mL of 0.5% lidocaine or 5 mL of lidocaine with 1 mL of steroid) were injected.

Inclusion and Exclusion Criteria
--------------------------------

Inclusion criteria focused on chronic lumbar axial or discogenic pain without disc herniation, radiculitis, facet joint pain, or sacroiliac joint pain in patients over 18 years of age with at least 6 months of function-limiting low back pain. The facet joint pain and sacroiliac joint pain were ruled out by controlled comparative local anesthetic blocks [@B4], [@B33]-[@B35], [@B39]-[@B42], whereas disc herniation was excluded by radiologic investigations and clinical assessment.

Exclusion criteria included previous lumbar surgery, central or foraminal spinal stenosis, radiculitis without disc herniation, facet joint pain, and sacroiliac joint pain.

Description of Interventions
----------------------------

All the procedures were performed in a sterile operating room under fluoroscopy by one physician with appropriate monitoring and intravenous sedation as indicated. Caudal epidural injections were performed by entering the epidural space through the sacral hiatus confirmed by contrast medium injection; whereas, lumbar interlaminar epidural injections were performed with the loss of resistance technique and confirmed under fluoroscopy with contrast medium injection.

Outcomes
--------

Outcome measurements were carried out at various periods up to 24 months with significant improvement defined as at least 50% improvement in pain relief and functional status.

The Numeric Pain Rating Scale (NRS) and Oswestry Disability Index (ODI), both of which are validated measures, were utilized in these trials [@B36], [@B37].

Sample Size
-----------

A sample size was determined for both randomized trials. A total of 110 patients, 55 patients in each group for each trial, were required. Considering a 0.05, 2-sided significance level, a power of 80%, an allocation ratio of 1:1, and accounting for a possible 10% attrition/noncompliance rate, 120 patients were included in each trial [@B36], [@B37].

Statistical Analysis
--------------------

The Statistical Package for Social Sciences version 9.01 (SPSS Inc, Chicago, IL) was utilized. Chi-square (Fisher\'s exact test where necessary) and *t* test were used for categorical and continuous data comparison, respectively. Patients\' outcomes were measured at 6 points in time, thus a repeated measures analysis of variance was performed with a post hoc analysis Bonferroni correction. A *P* value of less than 0.05 was considered significant.

An intent-to-treat analysis was performed after a sensitivity analysis in the original trials [@B36], [@B37].

Results
=======

Patient flow is shown in Fig. [1](#F1){ref-type="fig"} of both manuscripts [@B36], [@B37]. As described in these manuscripts, an intent-to-treat analysis was performed and all 60 patients in each trial were included in the analysis. There was an overall follow-up rate at the end of 2 years of 82% in the caudal trial and 78% in the lumbar interlaminar trial.

Recruitment
-----------

Patients were recruited from January 2007 through August 2008 for the caudal trial [@B35] and from January 2008 through May 2010 for the lumbar interlaminar trial [@B37].

Baseline Characteristics
------------------------

Baseline demographic and clinical characteristics of each trial are shown in Table [1](#T1){ref-type="table"}. There were no statistically significant differences between the caudal and lumbar interlaminar trials except for mean age and ODI scores.

Analysis of Outcomes
--------------------

### Pain Relief and Functional Assessment

Table [2](#T2){ref-type="table"} shows the comparative results of outcomes representing the results of repeated measures analysis of both trials over 24 months. There were no significant differences noted either in NRS or ODI scores with local anesthetic only compared to local anesthetic with a steroid or caudal compared to lumbar interlaminar epidurals. There were significant differences with improvement in all parameters from baseline to 24-month follow-up. However, the lumbar interlaminar group fared better when all patients were considered in reference to average total relief for one year and also for 2 years. Further, nonresponsive patients were inordinately high, with 42 in the caudal group, whereas there were only 11 in the lumbar interlaminar group.

Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} show the proportion of patients with significant improvement in pain and function of at least 50%. As shown in Figure [1](#F1){ref-type="fig"}, in the responsive patients, when local anesthetic was administered alone, significant improvement was seen in 78% in the lumbar interlaminar group and 84% in the caudal group compared to 70% and 73% at 24 months in patients who received local anesthetic with a steroid. A comparison of the results in all patients showed improvement with local anesthetic alone in 72% in the lumbar interlaminar group and 54% in the caudal group, whereas it was 67% and 60% with local anesthetic with a steroid at 24 months. Improvement was in a significantly higher proportion of patients receiving lumbar interlaminar injections of local anesthetic only at 12 months and 24 months.

Therapeutic Procedural Characteristics
--------------------------------------

Therapeutic procedural characteristics with procedural frequency, average relief per procedure, and average total relief in weeks over a period of 2 years is shown in Table [3](#T3){ref-type="table"}. Among the patients who were responsive, lumbar interlaminar and caudal injections both showed over 72 weeks average relief for 2 years compared to all patients who showed approximately 66 weeks in the lumbar interlaminar group and 53 weeks in the caudal group. The average procedures for 2 years was 6 with an average relief per procedure of 11 to 12 weeks. Lumbar interlaminar epidural injections were superior with an average total relief of one year and 2 years compared to caudal injections due to a high nonresponsive rate in the caudal trial.

Adverse Events
--------------

No major adverse events were reported in either trial.

Discussion
==========

This analysis shows the efficacy of caudal and lumbar interlaminar epidural injections for managing chronic persistent axial or discogenic pain without disc herniation, facet joint pain, or sacroiliac joint pain at 24 months in 54% and 60% of the patients in the caudal group who received local anesthetic only or local anesthetic with a steroid and 72% and 67% of the patients in the lumbar interlaminar group who received local anesthetic only or local anesthetic with a steroid. However, when only responsive patients were considered with improvement of at least 3 weeks with the 2 initial procedures, significant improvement was seen in 78% and 84% who received local anesthetic only in the lumbar interlaminar and caudal trials; whereas it was 70% and 73% for local anesthetic with a steroid. The proportion of patients improving when all patients were considered who received local anesthetic only was higher in the lumbar interlaminar group (54% versus 72%), whereas it was similar in patients who received local anesthetic with a steroid, as well as in responsive patients who received local anesthetic only or with a steroid. This may be explained by the fact that 11, or 9%, of the patients in the lumbar interlaminar group were shown to be nonresponsive, compared to 42, or 35%, of the patients in the caudal trial. Thus, once patients are judged to be responsive with the initial 2 injections, caudal and lumbar interlaminar epidural injections provide similar results of efficacy. These results also explain that it may be prudent to perform lumbar interlaminar epidural injections at least initially to judge responsiveness or a significant proportion of patients may be judged nonresponsive and may be denied further treatments.

When medically necessary and indicated, epidural injections may be repeated after the pain starts returning and pain relief and functional status improvement start dissipating below the 50% level in 10 to 12 weeks. Approximately 6 epidural injections per year are indicated in patients who demonstrate significant improvement with the first 2 procedures. These patients are considered to be responsive patients.

While lumbar disc herniation is relatively easily diagnosed and is the most common indication for surgical intervention, diagnosing discogenic pain is poorly defined and the diagnostic methods and treatments are controversial. Similar to disc herniation, the course and prognosis of discogenic pain is considered favorable, and by some, even better, than disc herniation.

Anatomically and pathophysiologically, the normal intervertebral disc is avascular and aneural, except for the outer third of the annulus fibrosis, which is innervated by sensory nerve endings from a dorsal root ganglion (DRG) [@B20]-[@B23]. Nevertheless, as the disc degeneration advances, disc inflammation promotes axonal growth of afferent fibers innervating the disc by secreting proinflammatory mediators, such as tumor necrosis factor and interleukin-6. Further, trophic growth factor for sympathetic and sensory nerve growth factor (NGF) also stimulate the differentiation, growth, maintenance, and survival of sympathetic and sensory nerve cells. NGF has been shown to exert hyperalgesic properties by sensitization of the sensory nerves, stimulation of peripheral nociceptive neurons growing into the intervertebral disc tissues triggering pain signals, and the neurons of DRG transmitting an inflammatory signal from the spinal cord to the pain centers of the brain. This response rate is similar to epidural injections for various conditions in multiple regions of the spine [@B43]-[@B51].

Based on widely available disc herniation literature from blind lumbar interlaminar trials, the evidence first favored caudal epidural injections, and later favored lumbar transforaminal epidural injections [@B4], [@B14]-[@B16]. Recent evidence shows similar efficacy for all 3 approaches for managing chronic disc herniation in the lumbar region [@B43], [@B45], [@B47], [@B49], [@B50]. However, there are also numerous publications with contradictory evidence, reporting a lack of efficacy for epidural injections for all pathologies utilizing all type of epidural injections - caudal, interlaminar, and transforaminal [@B52]-[@B58]. Similarly, this assessment of 2 trials [@B36], [@B37], conducted in a practical nonacademic setting with proper methodology, not only provides appropriate information, but also provides guidance in the proper application of interventions to reduce chronic discogenic pain, improve function, and potentially have a patient return to the workforce. However, results based on a lack of an appropriate protocol and procedural guidance, as well as inappropriate provision of any type of intervention, specifically inclusion of those that are not cost-effective, lead to substantial expenses, harms the health care environment, and, finally, harms patients and their access.

There have not been any randomized controlled trials for lumbar transforaminal epidural injections or other trials available for caudal or lumbar interlaminar epidural injections for managing chronic discogenic pain after excluding disc herniation, facet joint pain, and sacroiliac joint pain. This assessment essentially showed an equal efficacy in the patients who responded to the initial 2 procedures; there was a much smaller nonresponsive rate with a lumbar interlaminar approach versus a caudal approach (9% versus 35%). Further, there was no significant difference whether local anesthetics only were administered or if a steroid was added.

This assessment and the primary trials may be criticized for not performing provocation discographies to determine the presence of discogenic pain and/or internal disc disruption; however, based on the evidence thus far available in the literature [@B4], [@B22], [@B33]-[@B38], the major structures that can cause pain are intervertebral discs (without disc herniation), facet joints, and sacroiliac joints. Since the inclusion criteria consisted of only patients without disc herniation or radiculitis, and since subsequently facet joint and sacroiliac joint pain were also excluded, the inclusion criteria are considered appropriate. In addition, it has been always claimed that patients with less than 80% pain relief after diagnostic blocks may receive any further treatments due to a lack of approval of facet or sacroiliac joint interventions, but they have been shown to respond extremely well in this setting, similar to those with disc herniation, spinal stenosis, and post lumbar surgery syndrome [@B4], [@B14]-[@B16], [@B36]-[@B51].

In addition, practical clinical trials with a pragmatic approach which can be applied clinically and/or shown to be valid are considered essential for evidence-based medicine and comparative effectiveness research [@B4], [@B14]-[@B16], [@B36]-[@B51], [@B59], [@B60]. The present analysis of 2 randomized trials of discogenic pain may be criticized for multiple deficiencies, including 2 separate randomized trials utilized in this analysis, the lack of provocation discography prior to enrolling patients into the trials, and the lack of a placebo group in either trial. However, assessing the efficacy of caudal and lumbar interlaminar approaches in a single trial compromises patient, provider, and assessor blinding. Placebo design for interventional techniques is extremely difficult and multiple previous designs have been criticized for their inappropriate utilization in assessing epidural injections including caudal, interlaminar, and transformational approaches \[[@B4], [@B14]-[@B16]. Unlike epidural injections performed in managing disc herniation, there are no placebo trials available for discogenic pain either performed blindly or with fluoroscopy with any of the approaches. Multiple issues related to placebo-controlled trials are based on ample evidence that inactive substances, when injected into active structures, invariably result in various types of clinical effects, as well as placebo and nocebo effects [@B3], [@B4], [@B36]-[@B50], [@B53], [@B58]-[@B75]. In addition, local anesthetics also have shown long-term improvement or response that is similar to steroids in clinical and experimental settings [@B4], [@B14]-[@B16], [@B36]-[@B51], [@B76]-[@B78]. However, 2 appropriate placebo-designed trials have been described for interventional techniques [@B79], [@B80]. Thus, it is not only essential, but also mandatory, to design appropriate placebo studies in interventional pain management settings by injecting inactive solutions into inactive structures. Further, it is crucial to determine the improvement from baseline to follow-up periods rather than depending on between-group or between-trial differences and also not to consider either short-acting or even long-acting local anesthetics as placebos.

Conclusion
==========

This assessment shows that the 2 trials which included patients who failed to respond positively to the diagnostic criteria of 80% pain relief threshold responded with significant improvement in 78% or 70% with local anesthetic only or with a steroid in the lumbar interlaminar trial; whereas, the response rate was 84% and 73% in the caudal trial.
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###### 

Baseline demographic and clinical characteristics.

                                                 Interlaminar (120)   Caudal (120)   *P* value
  ---------------------------------- ----------- -------------------- -------------- -----------
  Gender                             Male        32% (38)             29% (35)       0.673
  Female                             68% (82)    71% (85)                            
  Age                                Mean ± SD   42.0 ± 11.6          46.2 ± 14.3    0.013
  Weight                             Mean ± SD   189.9 ± 55.8         183.3 ± 51.9   0.344
  Height                             Mean ± SD   66.1 ± 3.9           65.5 ± 3.7     0.218
  Body Mass Index                    Mean ± SD   30.5 ± 8.5           29.9 ± 7.9     0.599
  Duration of Pain (months)          Mean ± SD   116.6 ± 99.4         95.5 ± 86.0    0.080
  Onset of Pain                      Gradual     68% (82)             65% (78)       0.681
  Injury                             32% (38)    35% (42)                            
  Numeric Pain Rating Scale Scores   Mean ± SD   7.8 ± 0.9            8.0 ± 0.9      0.242
  Oswestry Disability Index Scores   Mean ± SD   29.9 ± 4.9           28.3 ± 4.9     0.014

###### 

Comparative results of Numeric Pain Rating Scale scores and Oswestry Disability Index scores for 2 years (Mean ± SD) of lumbar interlaminar and caudal epidural injections.

                     Numeric Pain Rating Scale   Oswestry Disability Index                  
  ------------------ --------------------------- --------------------------- -------------- --------------
                     Interlaminar                Caudal                      Interlaminar   Caudal
  Baseline           7.8 ± 0.9                   8.0 ± 0.9                   29.9 ± 4.9     28.3 ± 4.9
  3 months           3.5\* ± 1.0                 3.9\* ± 1.6                 14.7\* ± 4.7   15.4\* ± 6.5
  6 months           3.7\* ± 1.1                 3.9\* ± 1.7                 14.9\* ± 5.0   15.3\* ± 7.0
  12 months          3.7\* ± 1.2                 4.1\* ± 1.7                 15.0\* ± 5.7   15.4\* ± 6.9
  18 months          3.9\* ± 1.3                 4.2\* ± 1.8                 14.9\* ± 5.5   15.5\* ± 7.1
  24 months          3.7\* ± 1.4                 4.2\* ± 1.8                 14.7\* ± 5.6   15.7\* ± 7.1
  Group Difference   0.240                       **0.011**                                  
  Time Difference    0.001                       0.000                                      

A lower value indicates better condition.

\* significant difference with baseline values within the group (*P* \< 0.001).

###### 

Therapeutic procedural characteristics with procedural frequency, average relief per procedure, and average total relief in weeks over a period of 2 years.

                                               Responsive Patients   Nonresponsive Patients   All Patients                                               
  -------------------------------------------- --------------------- ------------------------ ------------------- ----------------- -------------------- ------------------
                                               Interlaminar (109)    Caudal (78)              Interlaminar (11)   Caudal (42)       Interlaminar (120)   Caudal (120)
  Average Number of Procedures for One Year    4.0 ± 0.9             4.0 ± 1.0                1.9 ± 1.2           2.8 ± 1.5         3.8\* ± 1.1          3.6 ± 1.3
  Average Number of Procedures for Two Years   6.4 ± 2.2             6.1 ± 2.2                1.9 ± 1.2           3.1 ± 2.0         6.0\* ± 2.5          5.0 ± 2.5
  Average Relief for First procedure           6.3 ± 4.1             6.8 ± 5.4                0.7 ± 0.9           1.9 ± 2.3         5.8 ± 4.2            5.1 ± 5.1
  Average Relief for Second Procedure          10.6 ± 10.5           12.2 ± 11.6              0.9 ± 1.0           1.6 ± 1.9         10.1 ± 10.5          9.0 ± 10.9
  After Initial 2 Procedures                   12.7 ± 3.6 (475)      13.4 ± 7.2 (316)         3.2\* ± 3.3 (5)     8.7 ± 5.8 (53)    12.6 ± 3.7 (480)     12.7 ± 7.2 (369)
  Average Relief per Procedure                 11.4 ± 5.8 (693)      12.1 ± 8.2 (472)         1.3\* ± 2.0 (21)    4.6 ± 5.3 (129)   11.1 ± 6.0 (714)     10.5 ± 8.2 (601)
  Average Total Relief for One Year (Weeks)    39.3 ± 12.3           42.0 ± 9.9               2.5 ± 4.0           10.1 ± 12.2       35.9\* ± 15.9        30.8 ± 18.6
  Average Total Relief for Two Years (Weeks)   72.2 ± 29.2           73.0 ± 28.1              2.5 ± 4.0           14.3 ± 22.7       65.8\* ± 34.4        52.9 ± 38.3

\* - Significant difference with caudal epidurals.
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